BAs influence IBD progression primarily by engaging specific receptors, notably Takeda G protein-coupled receptor 5 (TGR5) and the farnesoid X receptor (FXR), to preserve intestinal barrier integrity. Here, GPBAR1 is linked to inflammatory bowel disease.